GcMAF immunotherapy and complmentary treatments at Saisei Mirai
Dr.Toshio Inui and Dr Kentaro Kubo gave prsentation about clinical use of GcMAF (+ Oral Colostrum MAF), and Skin cell injection therapy in Norrkoping, Sweden on May 29, 2018.
We hope that you found the conference informative and worthwhile.
Your presence helped to make this event a great success and your enthusiasm and positive spirit helped make our time together both productive and fun.
We wish you all the best and hope that you continue to be with the the Saisei Mirai.
→ Saisei Pharma
Apr 09, 2018 Seminar
Apr 11, 2018 Seminar
Dr. Antonio Jimenez, Chief Medical Officer of Hope4Cancer Treatment Centers, presents "The Importance of Emotions in Cancer" at a conference in Beaumont, Texas (Jan 2018).
Dr. Antonio Jimenez presenting at the “Un Mundo Sin Cancer” (“A World Without Cancer”) conference in Barcelona, Spain (Jan 2018).
Dr. Antonio Jimenez being interviewed in the Fox News Morning Show at Beaumont, Texas (Jan 2018).
2017 Integrative Medical Therapies conference - Osaka, Japan
→ Establishment of a Macrophage-activating Factor Assay System Using the Human Monocytic Cell Line THP-1
→ A Novel Assay System for Macrophage-activating Factor Activity Using a Human U937 Cell Line
Purchase your Colostrum MAF here using PayPal or credit card.Heart Pharmacy website
Thank you very much for your participation at the Saisei Mirai 2016 Integrative Medical Therapies conference in Osaka, held on Sunday 13th November 2016.2016 Integrative Medical Therapies conference - Osaka, Japan
Dr Toshio Inui
Dr. Toshio Inui gave a presentation of the electric field therapy and second-generation GcMAF and colostrum MAF at a conference which was held in Jakarta, Indonesia on July 22, 2016.
14 to 15-JUL-2016
Dr. Shinichiro Akiyama at International Pharmacy Conference, which was held in the United States Philadelphia, Pennsylvania on July 14 to 15, 2016, the Clinical experience of colostrum derived protein against solid cancer has been announced as the Keynote Speaker.
2016 Case Report: GcMAF Treatment in a Patient with Multiple Sclerosis (PDF)
ANTICANCER RESEARCH 36: 3771-3774 (2016)
2016 Case Report: A Non-small Cell Lung Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Tumor Treating Fields (PDF)
ANTICANCER RESEARCH 36: 3767-3770 (2016)
2016 Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors (PDF)
ANTICANCER RESEARCH 36: 3619-3624 (2016)
New research papers on Oral Colostrum GcMAF for Chronic Fatigue Syndrome (CFS) and serious infection published in Anticancer Research journal.Research paper
2015 Oral Colostrum Macrophage-activating Factor for Serious Infection and Chronic Fatigue Syndrome: Three Case Reports (PDF)
Anticancer Res August 2015 35 (8) 4545-4549
Clinical application of Second Generation GcMAF and oral GcMAF
Dr Toshio Inui
Indications for GcMAF for immunotherapy of cancers and chronic viral and bacterial infections (PDF)
Dr Toshio Inui
Case Report: A Breast Cancer Patient Treated with GcMAF, Sonodynamic Therapy and Hormone Therapy (PDF), PPT
Dr Toshio Inui
New research papers on GcMAF and integrative cancer immunotherapy treatment written in collaboration with the University of Tokushima, Kanazawa University and Kobe University Graduate School of Medicine researchers and Saisei Mirai published in Anticancer Research journal.Research paper
2013 Degalactosylated/Desialylated Human Serum Containing GcMAF Induces Macrophage Phagocytic Activity and In Vivo Antitumor Activity (PDF)
Anticancer Res July 2013 33 (7) 2881-2885
2013 Clinical Experience of Integrative Cancer Immunotherapy with GcMAF (PDF)
Anticancer Res July 2013 33 (7) 2917-2919
Experiment report of Gc MAF stability assay
14-JUN-2012 Stability of GcMAF in Serum (PDF)
H Mukai, Y Uto. Department of Biological Science and Technology, The University of Tokushima.
The results show that 2nd Generation GcMAF is stable for 1 year at 4 °C, for 14 days at room temperature (around 20 °C), and for 7 days at 40 °C.
See Research and references for more details on experiments on macrophage phagocytic activity and stability of our GcMAF.
Collaborations with the University of Tokushima
We collaborate with GcMAF researchers at the University of Tokushima, Japan in the development of second generation GcMAF. See Research and references for published research papers on Gc-MAF in peer-reviewed scientific journals authored by the University of Tokushima researchers over the last decade. Our research on GcMAF is ongoing and papers are being prepared for publication in collaboration between the University of Tokushima and Saisei Mirai in the next few months.
- Professor Hitoshi Hori, Institute of Technology and Science, The University of Tokushima, Tokushima, Japan.
- Associate professor, Yoshihiro Uto, Institute of Technology and Science, The University of Tokushima, Tokushima, Japan.
- Professor Norihiro Sakamoto, National University Hospital, Kobe University School of Medicine, Kobe, Japan.
- Professor Yoshinori Marunaka, Kyoto Prefectural University of Medicine, Kyoto, Japan.
- Professor Yoshito Nishikata, Faculty of Science, Konan University, Kobe, Japan.
- Kentaro Kubo, PhD., Saisei Mirai Cell Processing Center, Osaka, Japan.